Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma

Su, Hengchuan; Sun, Tiantian; Wang, Hongkai; Shi, Guohai; Zhang, Hai-Liang; Sun, Fenyong; Ye, Dingwei

doi:10.18632/oncotarget.11011

Cited by 48 publications

(46 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low level of TCL6 was associated with worse overall and disease-free survival of RCC patients. These findings were consistent with a previous study, TCL6 was reported to be negatively correlated with the T, N, M, and TNM stage and serve as an independent predictor via analysis of 71 pairs of RCC samples [19].…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Long non-coding RNA TCL6 enhances preferential toxicity of paclitaxel to renal cell carcinoma cells

Chen¹,

Zhuang²,

Cheng³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: Recent findings have shown long non-coding RNAs (lncRNAs) are dysregulated in a variety of cancer cells. In this report, we investigate the effect of T-cell leukemia lymphoma 6 (TCL6) on paclitaxel (PTX)-induced apoptosis in Renal cell carcinoma (RCC) cells. Methods: Expression levels of TCL6 in RCC tissues were analyzed via The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Fluorescence in situ hybridization (FISH) was performed to detect the expression of TCL6 in RCC tissues and cells. Two pairs of cell lines were used: TCL6-silenced 786-O cell line and scrambled 786-O cell line, TCL6-overexpressed Caki-1 cell line and Caki-1 scrambled cell line. Cell viability was detected using the MTT assay. Apoptosis was examined by flow cemetery. Dual reporter gene assay was performed to confirm the direct downstream target miRNA of TCL6. Results: Based on RNA sequencing expression data of RCC tissues from TCGA and GEO datasets, the expression deficiency of TCL6 was observed in RCC tissues. Low level of TCL6 was associated with worse overall and disease-free survival of RCC patients. The FISH showed similar results with low expression of TCL6 in RCC tissues and cells. After PTX treatment, a time-dependent decrease in cell viability was observed in TCL6-overexpressed RCC cells and an increase in cell viability was observed in TCL6-silenced cells compared to control cells. Apoptosis induced by PTX was significantly increased in TCL6-overexpressed cells. Inhibition of TCL6 showed a significant decrease in apoptosis. Furthermore, luciferase reporter assay revealed that TCL6 is a direct target gene of miR-221. Conclusions: TCL6 effectively sensitizes RCC to PTX mainly through downregulation of miR-221. Our results suggest that PTX combined with TCL6 might be a potentially more effective chemotherapeutic approach for renal cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

“…SuperScript II Reverse Transcriptase kit (Invitrogen Life Technologies) was used to generate cDNA. Quantitative real-time PCR analyses were performed according to previous study [19]. Samples were compared using the relative CT method, where the relative expression of TCL6 was normalized to that of GAPDH.…”

Section: Quantitative Real-time Rt-pcrmentioning

confidence: 99%

Long non-coding RNA TCL6 enhances preferential toxicity of paclitaxel to renal cell carcinoma cells

Chen¹,

Zhuang²,

Cheng³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…The three RCC subtype cohorts were further divided into high PD-L1 group and low PD-L1 group based on the median PD-L1 mRNA value (Table 1) [15, 16]. …”

Section: Resultsmentioning

confidence: 99%

Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues

Ning

Gong

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Renal cell carcinoma is one of the most common urological tumors. The role of programmed cell death 1 ligand 1 (PD-L1) in renal cell carcinomas in predicting outcome of the patients is yet unclear. We analyzed the clinical and RNA-seq data of 522 kidney clear cell cancer, 259 kidney papillary cell carcinoma and 66 kidney chromophobe patients from The Cancer Genome Atlas (TCGA) database. In kidney clear cell cancer patients with high PD-L1 mRNA level and low PD-L1 mRNA level in tumors, the median overall survival periods were 45.0 and 37.1 months respectively (p=0.002). Multivariate Cox regression tests found that PD-L1 mRNA level in tumor was an independent predictor for overall survival status in kidney clear cell cancer patients (HR=0.7, 95% CI 0.5-0.9, p=0.007). However, no significant difference in overall survival status was found between high and low PD-L1 groups in kidney papillary cell carcinoma and kidney chromophobe cohorts. Gene-set enrichment analysis on the data from databases of TCGA and GSE53757 dataset in Gene Expression Omnibus databases showed that several pathways relating to immunological functions were activated in kidney clear cell cancers with high PD-L1 mRNA expression, and glycolysis and epithelial-mesenchymal transition pathways relating to tumor progression and metastasis were increased in kidney clear cell cancers with low PD-L1 mRNA level. In conclusion, higher PD-L1 mRNA level in kidney clear cell cancer tissues was associated with a favorable outcome due to the higher immunological responses in tumor tissues.

show abstract

“…Recently, it was reported that DLEU2 was involved in several types of cancer and DLEU2 exon 9 was an independent marker of poor prognosis in patients with esophageal adenocarcinoma (31). Aberrant expression levels of TCL6 were involved in clear cell renal carcinoma by regulating the PI3K/AKT pathway and PWRN1 inhibits gastric cancer cell proliferation and metastasis via p53 signaling pathway (32,33).…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis of prognosis-related long non-coding RNAs in invasive breast carcinoma

Yin

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Breast cancer is one of the most common types of cancer among women worldwide and needs more sensitive prognostic biomarkers to improve its treatment. In the present study, differentially expressed long non-coding RNAs (lncRNAs) in invasive breast carcinoma from The Cancer Genome Atlas and cBioPortal database were investigated, identifying 292 differentially expressed lncRNAs in 1,100 cases. By analyzing the overall survival rate, 10 lncRNAs were significantly correlated with poor prognosis. To explore the underlying molecular mechanisms of the 10 prognosis-related lncRNAs, bioinformatic methods were used to predict the potential target miRNAs, mRNAs and proteins, and to construct a lncRNA-miRNA-mRNA regulatory network and lncRNA-protein interaction network. Finally, the functions of the target genes and proteins were insvestigated using Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analyses. The results showed that these 10 lncRNAs could be novel prognostic markers for invasive breast carcinoma and the present study aimed to provide novel insight into the diagnosis and treatment of breast cancer.

show abstract

Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma

Cited by 48 publications

References 18 publications

Long non-coding RNA TCL6 enhances preferential toxicity of paclitaxel to renal cell carcinoma cells

Long non-coding RNA TCL6 enhances preferential toxicity of paclitaxel to renal cell carcinoma cells

Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues

Bioinformatics analysis of prognosis-related long non-coding RNAs in invasive breast carcinoma

Contact Info

Product

Resources

About